Femasys, Inc. (FEMY)

Over the past six months, Femasys's stock price has experienced volatility and a decline. In November 2025, Femasys secured FDA approval to advance the final FemBloc trial phase and announced $12 million in financing. In October 2025, the company initiated a post-market surveillance study for FemBloc in Europe and regained compliance with Nasdaq's minimum equity requirement. In August 2025, Femasys secured UK regulatory approval for FemBloc and conducted an $8 million offering. In May 2025, a smaller financing offering also occurred. The company's Q3 2025 revenue of $0.73 million significantly missed Wall Street consensus estimates.

Information regarding specific demand seasonality for Femasys, Inc.'s products and services is not explicitly detailed. While some sources mention that FEMY's seasonality displays mean and median monthly returns to identify seasonal patterns, the actual patterns or their impact on demand are not described.

Femasys, Inc. is a biomedical company focused on developing therapeutic and diagnostic solutions for women's healthcare needs in the United States and internationally. The company operates in the Health Care sector, specifically in the Health Care Equipment and Medical Instruments & Supplies industries. Femasys's product portfolio includes minimally invasive, in-office solutions such as FemaSeed, FemVue, FemCerv, FemCath, FemChec, and FemBloc.

Femasys, Inc. develops and offers its solutions in the United States and internationally. The company is expanding its presence in European markets, particularly with its FemBloc product, through regulatory approvals and distribution partnerships.

Femasys maintains a generally positive brand reputation within the analyst community, with a consensus rating of "Strong Buy" or "Moderate Buy". Analysts have an average price target of $5.78 to $6.83. Positive events include FDA approval to advance the final FemBloc trial phase, UK and European regulatory approvals for FemBloc, distribution partnerships in Europe for FemBloc, FDA clearance for FemChec, and the launch of Femsperm analysis and insemination prep kits. The slower-than-anticipated commercial ramp-up for products and the significant revenue miss in Q3 2025 could be perceived as challenges.

Femasys is primarily owned by retail investors, who hold 89.54% of the company's stock. Institutional shareholders own 6.41%, and Femasys insiders hold 4.05%. Major institutional owners include Dauntless Investment Group, LLC, Vanguard Group Inc., Geode Capital Management, LLC, Clear Creek Financial Management, LLC, BlackRock, Inc., Northern Trust Corp, and State Street Corp. Edward R. Uzialko is the largest individual shareholder, owning 1.22 million shares.